Latest news

• EMA concludes GSK, Vir’s mAb can be used to treat high-risk COVID-19 patients

  The recommendations come following a review of data, including from a study evaluating the effects of VIR-7831 in adult outpatients with mild COVID-19 symptoms. ... According to a planned interim analysis of this study, VIR-7831 reduced the risk of

• EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19

  and with other antibodies, including VIR-7831, versus placebo in low-risk adults with mild-to-moderate COVID-19. ... An interim analysis demonstrated that bamlanivimab plus VIR-7831 resulted in a 70% relative reduction of patients with persistently high

• GSK’s revenue drops by 18% in Q1 as performance pressures mount

  Another partnership with Vir Biotech for a COVID-19 monoclonal antibody (mAb) should also begin to yield sales, with the European Medicines Agency currently reviewing the company's VIR-7831 for

• Lilly, Vir and GSK’s antibodies reduce viral load by 70% in low-risk COVID-19 patients

  Bamlanivimab administered with VIR-7831 also demonstrated a statistically significant reduction in key virologic secondary endpoints compared to placebo. ... This virology data supports our belief that bamlanivimab and VIR-7831 together could be a

• GSK, Vir seek EUA after scoring positive results for COVID-19 antibody VIR-7831

  VIR-7831 reduced the risk of hospitalisation/death by 85% in high-risk COVID-19 patients. ... As a result, the independent data and safety monitoring board (DSMB) has recommended that enrolment for the VIR-7831 arm of the trial should be paused while the